Skip to content
GeoClinicalTrials
Back to search

NCT06408688Recruiting

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

Official recordSimplified version

Summary

The main objective of this study is to test if adding the mistletoe extract Iscador® Qu to regular cancer treatment with immune checkpoint inhibitors affects: * The immune system's ability to fight cancer * Safety of the treatment * How well the treatment performs against cancer * How the patient feels during treatment Researchers will compare patients treated with immune checkpoint inhibitors plus Iscador® Qu with patients treated with imune checkpoint inhibitors only.

Inclusion criteria

• Locally advanced non-operable or metastatic solid tumor, except for skin cancer • Eligible for routine (standard) treatment with immune checkpoint inhibitor (+/- chemo/targeted therapy) as per the discretion of the local investigator • Subjects must be eligible for treatment with mistletoe preparations (controlled brain metastases, prednisolone equivalent below 10mg, no known hypersensitivity) • ECOG (Eastern Cooperative Oncology Group) performance status score of 0-2 • Males and Females at least 18 years of age; no subjects under tutelage • No previous mistletoe treatment

Exclusion criteria

• Contraindications to Iscador® Qu or immune checkpoint inhibitors, e.g. hypersensitivity, active autoimmune disorder • Patients with skin cancer • Participation in another study with investigational drug within 30 days prior to enrolment (participation in observational studies or diagnostic studies without a particular drug intervention are allowed) • Enrolment of the investigator, his/her family members, employees and other dependent

Contacts

The trial team's contact details are shown on request.

See the official trial record
Status
Recruiting
Phase
Phase 4
Study type
Interventional
Countries
Switzerland
Sponsor
University Hospital, Basel, Switzerland(Other)
Protocol no.
2023-02373; th23binder
Conditions
Advanced Solid Tumor
Interventions
Drug

Treatments studied

  • Immune checkpoint inhibitors plus Iscador® Qu.
  • Immune Checkpoint Inhibitors

Locations · 4

  • Baden, SwitzerlandKantosspital Baden AGRecruiting at this site
  • Basel, SwitzerlandUniversitätsspital BaselRecruiting at this site
  • Liestal, SwitzerlandKantonsspital BasellandRecruiting at this site
  • Sankt Gallen, SwitzerlandTumor- und Brustzentrum OstschweizRecruiting at this site

In total, worldwide, all 4 sites listed in the registry are recruiting.

Site status per the ClinicalTrials.gov registry (last update posted: December 27, 2024).

This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.

Other identifiers

  • 2023 · NIH grant

See also

Other versions

These results are indicative and do not replace medical advice — discuss them with your doctor.